Beijing Sun-Novo Pharmaceutical Research Future Growth
Future criteria checks 6/6
Beijing Sun-Novo Pharmaceutical Research is forecast to grow earnings and revenue by 37.2% and 27.2% per annum respectively. EPS is expected to grow by 43.7% per annum. Return on equity is forecast to be 25.1% in 3 years.
Key information
37.2%
Earnings growth rate
43.7%
EPS growth rate
Life Sciences earnings growth | 29.4% |
Revenue growth rate | 27.2% |
Future return on equity | 25.1% |
Analyst coverage | Low |
Last updated | 27 Feb 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1,659 | 422 | N/A | N/A | 3 |
12/31/2024 | 1,272 | 304 | N/A | N/A | 1 |
12/31/2023 | 954 | 194 | N/A | N/A | N/A |
9/30/2023 | 873 | 198 | 45 | 123 | N/A |
6/30/2023 | 813 | 187 | -55 | 24 | N/A |
3/31/2023 | 761 | 170 | -83 | 17 | N/A |
12/31/2022 | 677 | 156 | 0 | 104 | N/A |
9/30/2022 | 648 | 149 | -91 | 51 | N/A |
6/30/2022 | 594 | 134 | -55 | 84 | N/A |
3/31/2022 | 546 | 119 | -19 | 86 | N/A |
12/31/2021 | 494 | 106 | 3 | 88 | N/A |
9/30/2021 | 454 | 107 | 23 | 61 | N/A |
6/30/2021 | 416 | 91 | 38 | 65 | N/A |
3/31/2021 | 369 | 76 | 14 | 51 | N/A |
12/31/2020 | 347 | 72 | 36 | 63 | N/A |
12/31/2019 | 234 | 47 | 31 | 57 | N/A |
12/31/2018 | 135 | 21 | 28 | 44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688621's forecast earnings growth (37.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 688621's earnings (37.2% per year) are forecast to grow faster than the CN market (23.8% per year).
High Growth Earnings: 688621's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688621's revenue (27.2% per year) is forecast to grow faster than the CN market (14.4% per year).
High Growth Revenue: 688621's revenue (27.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688621's Return on Equity is forecast to be high in 3 years time (25.1%)